Who is sponsoring NCT04241198?

NCT04241198 is sponsored by Notal Vision Ltd..

Is NCT04241198 still recruiting?

NCT04241198 is currently completed. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT04241198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Home Retinal Imaging Using NOTAL-OCT V3.0

Completed Last updated 15 June 2023

What this trial tests

trial in A. AMD Patients, Where at Least One Eye is With Active CNV, Presenting Retinal Fluid at the Enrolment Visit, Undergoing Active Anti-VEGF Treatment in 10 participants. Completed in 28 March 2023.

Timeline

9 June 2020

Primary endpoint
30 July 2022

28 March 2023

Quick facts

Lead sponsor	Notal Vision Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10
Start date	9 June 2020
Primary completion	30 July 2022
Estimated completion	28 March 2023
Sites	1 location across Israel

Conditions studied

A. AMD Patients, Where at Least One Eye is With Active CNV, Presenting Retinal Fluid at the Enrolment Visit, Undergoing Active Anti-VEGF Treatment — all drugs for A. AMD Patients, Where at Least One Eye is With Active CNV, Presenting Retinal Fluid at the Enrolment Visit, Undergoing Active Anti-VEGF Treatment →

Sponsor

Notal Vision Ltd.

Who can join

18 and older, any sex, with A. AMD Patients, Where at Least One Eye is With Active CNV, Presenting Retinal Fluid at the Enrolment Visit, Undergoing Active Anti-VEGF Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will include up to 30 AMD patients, recruited by two medical centers, Tel-Aviv medical center and Assuta Hashalom medical center. At the screening visit, the patients will be imaged in their tested, eligible eye(s), using a commercial Zeiss Cirrus or Heidelberg Spectralis OCT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective, Longitudinal Pilot Study: Daily Self-Imaging with Patient-Operated Home OCT in Neovascular Age-Related Macular Degeneration.
Keenan TDL, Goldstein M, Goldenberg D, Zur D, et al · · 2021 · cited 40× · PMID 36249303 · DOI 10.1016/j.xops.2021.100034

Verify or expand the search:

Other Notal Vision Ltd. trials

Trials by the same sponsor.

NCT04078672 — Retinal Imaging Using NOTAL-OCT V3.0 · NA · completed
NCT03969303 — NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients · completed
NCT03600519 — Retinal Imaging Using NOTAL-OCT V2.5 · completed
NCT03270865 — Usability and Ergonomic Evaluation of Self-Positioning System for Retinal Imaging · NA · completed
NCT03030729 — Macular Thickness Measurements Using Retinal-thickness OCT · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04241198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Notal Vision Ltd.
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04241198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing